Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 5/20 | 0.36 |
| ▸ | METAP1 | P53582 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23129041 | 1.00 | KIF11 (0.40) | KIF11METAP2METAP1CA1CA2 | |
| SCHEMBL1709954 | 0.90 | KIF11 (0.38) | KIF11METAP2METAP1CA1CA2 | |
| SCHEMBL10680756 | 0.83 | METAP2 (0.42) | METAP2METAP1 | |
| SCHEMBL23542532 | 0.83 | METAP2 (0.42) | METAP2METAP1 | |
| SCHEMBL16847765 | 0.82 | KIF11 (0.39) | KIF11TLR2SMN1; SMN2NOS1NOS2 | |
| SCHEMBL8198081 | 0.82 | KIF11 (0.39) | KIF11METAP2METAP1TLR2SMN1; SMN2 | |
| SCHEMBL4195079 | 0.82 | ARG1 (0.47) | KIF11NOS1NOS2NOS3ARG1 | |
| SCHEMBL14614801 | 0.82 | KIF11 (0.39) | KIF11METAP2METAP1TLR2SMN1; SMN2 | |
| SCHEMBL929643 | 0.81 | KIF11 (0.37) | KIF11SMN1; SMN2ARG1ARG2 | |
| SCHEMBL14160472 | 0.81 | KIF11 (0.37) | KIF11SMN1; SMN2ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029469-A1 | CYCLOSPORIN ANALOGS | ALLERGAN, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9493511-B2 | Cyclosporin analogs | ALLERGAN, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150065433-A1 | CYCLOSPORIN ANALOGS | ALLERGAN, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20120088734-A1 | Cyclosporin Analogs | ALLERGAN, INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065433-A1 | CYCLOSPORIN ANALOGS | CHP1, TSLP, PPP3R1 | KIF11 4692/4885METAP2 2986/4885METAP1 2496/4885 |
| US-20120088734-A1 | Cyclosporin Analogs | CHP1, TSLP, PPP3R1 | KIF11 4692/4885METAP2 2986/4885METAP1 2496/4885 |
| US-20170029469-A1 | CYCLOSPORIN ANALOGS | CHP1, TSLP, PPP3R1 | KIF11 4692/4885METAP2 2986/4885METAP1 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.